Previous Close | 0.00 |
Open | 19.40 |
Bid | 17.60 x 40000 |
Ask | 20.47 x 40000 |
Day's Range | 19.40 - 19.40 |
52 Week Range | 13.19 - 20.83 |
Volume | |
Avg. Volume | 6,032 |
Market Cap | 28.342B |
Beta (5Y Monthly) | 0.45 |
PE Ratio (TTM) | 35.06 |
EPS (TTM) | 0.52 |
Earnings Date | Nov 07, 2024 |
Forward Dividend & Yield | 0.17 (0.96%) |
Ex-Dividend Date | Mar 28, 2025 |
1y Target Est | N/A |
TOLEDO, Ohio & TOKYO, October 15, 2024--NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering end-to-end market access services, and TERUMO, a global leader in medical technology, announced that they have entered into a strategic outsourcing partnership aimed at accelerating the regulatory approval and commercialization of Terumo’s product portfolio.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.